|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Drug Development & Delivery recently interviewed Josh Marsh, Bioavailability Enhancement and PBPK Lead Scientist at Lonza, to discuss the benefits of predictive tools and Lonza’s approach.
|
|
 |
|
Drug Development & Delivery recently interviewed Ofer Gonen, Chief Executive Officer of MediWound, to discuss the company’s innovative approach to debridement.
|
|
 |
|
Significant growth in the drug delivery sector is predicted for many areas, with headliners including cell and gene therapies and the GLP-1 blockbusters. Small molecule-based formulations still dominate innovator pipelines, but advanced biologics are also….
|
|
 |
|
As regulations continue to change around cosmetic and pharmaceutical-grade excipients, the pharmaceutical industry has choices to make when investing in quality, risk, and public safety.
|
|
|
|
|
|
|
|
|
Mark Bleackley, PhD, says as time goes on, more companies will discover the benefits of drug repurposing – and how to successfully use such strategies to develop new, patentable drug products. In fact, repurposing could be exactly what’s needed to enable pharmaceutical and biotechnology companies to more swiftly develop treatments for indications with significant unmet medical needs.
|
|
|
Nicolas Buchmann, PhD, explores the opportunities and challenges of developing biologic formulations for delivery via SMIs and discusses the importance and impact of partnerships between inhalation device development experts when it comes to facilitating the innovation needed to expand the suitability of SMIs to a wider range of biopharma formulations.
|
|
|
Anette Müllertz, PhD, Grace Furman, PhD, and Lisa Caralli say developers should first understand the developability challenges for their molecule, then a toolkit of enabling technologies can be identified to overcome those factors and individually leveraged to create fit for purpose formulations for use in preclinical and clinical studies.
|
|
|
Ronald Aung-Din, MD, Sasha Feygin, and Daniele La Rosa say Direct Effects topical perampanel is effective in treating headache and other neurological symptoms commonly encountered in patients with seizures and other conditions in which neuronal instability and hyper-excitability exist.
|
|
|
Scott Schobel, MD, and Nicole Datson, PhD, are hopeful their novel platform for targeting disease-causing RNA with multiple modulating approaches will lead to major advances in treating genetic disease and improving the lives of patients and their families in the years ahead.
|
|
|
|
|
|
|
|
|

Phosphorex, a leading CDMO located just 26.2 miles from Boston in Hopkinton, MA. Our state-of-the-art facility spans at 30,000 Sq. Ft., with an additional 12,000 Sq. Ft. of cGMP space set to come online in 2025. With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development. Click here for more.
|
|
|
|
|
|
 |
|
Whether you’re involved in research, development, or quality control, this webinar will equip you with the knowledge and tools you need to enhance your analytical processes and ensure success in your LNP projects.
|
|
 |
|
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
|
|
|
|
|
|
|
|
 |
|
Drug-eluting implants offer a unique approach to overcoming challenges associated with traditional drug delivery methods. They can provide sustained, continuous release of a therapeutic at the desired site of action.
Download our latest white paper, jointly authored with MeltPrep, to …
|
|
 |
|
By: Jasmine Musakhanian, Senior Scientific Director, Gattefossé
INTRODUCTION
Mono and diglycerides, also known as partial glycerides, are versatile lipid excipients that play a pivotal role in the realization of drug products and nutraceuticals. Some well-known excipients in this category are …
|
|
 |
|
It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies used to overcome solubility issues in active …
|
|
|
|
|
Upcoming eNewsletter Features:
October 30 – Formulation Development
November 6 – Drug Delivery
|
|
|
|
|
|
|
|